• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Oral Anticoagulation with VKAs: Quality Above All!使用维生素K拮抗剂进行口服抗凝治疗：质量至上！
Arq Bras Cardiol. 2025 Feb;122(2):e20240795. doi: 10.36660/abc.20240795.
2
Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.癌症患者静脉血栓栓塞症长期治疗的抗凝治疗
Cochrane Database Syst Rev. 2018 Jun 19;6(6):CD006650. doi: 10.1002/14651858.CD006650.pub5.
3
Warfarin and atrial fibrillation: from ideal to real the warfarin affaire.华法林与心房颤动：从理想走向现实——华法林的故事。
Thromb J. 2014 Feb 18;12(1):5. doi: 10.1186/1477-9560-12-5.
4
Living on Oral Anticoagulants: Duke Anticoagulation Satisfaction Scale Results.口服抗凝剂治疗的生活体验：杜克抗凝满意度量表结果
J Clin Med. 2023 Dec 8;12(24):7574. doi: 10.3390/jcm12247574.
5
Anticoagulation for Patients With Concomitant Atrial Fibrillation and End-Stage Renal Disease: A Systematic Review and Network Meta-Analysis.伴有房颤和终末期肾病患者的抗凝治疗：系统评价和网络荟萃分析。
J Am Heart Assoc. 2024 Apr 16;13(8):e034176. doi: 10.1161/JAHA.123.034176. Epub 2024 Apr 12.
6
Bleeding and thrombotic outcomes associated with postoperative use of direct oral anticoagulants after open peripheral artery bypass procedures.开放外周动脉旁路手术后使用直接口服抗凝剂与出血和血栓形成结局的相关性。
J Vasc Surg. 2020 Dec;72(6):1996-2005.e4. doi: 10.1016/j.jvs.2020.02.021. Epub 2020 Apr 8.
7
Factors Affecting the Quality of Anticoagulation With Vitamin K Antagonists in Venous Thromboembolism Patients.影响静脉血栓栓塞症患者维生素K拮抗剂抗凝质量的因素
Biol Res Nurs. 2017 Mar;19(2):198-205. doi: 10.1177/1099800416671211. Epub 2016 Sep 28.
8
Direct Oral Anticoagulants (DOACs) are Non-Inferior to Vitamin K Antagonists for Patients Undergoing Transcatheter Aortic Valve Replacement with Indications of Anticoagulation.对于有抗凝指征的经导管主动脉瓣置换术患者，直接口服抗凝剂（DOACs）不劣于维生素K拮抗剂。
Rev Cardiovasc Med. 2022 Oct 17;23(10):346. doi: 10.31083/j.rcm2310346. eCollection 2022 Oct.
9
Gut Microbiota and the Quality of Oral Anticoagulation in Vitamin K Antagonists Users: A Review of Potential Implications.肠道微生物群与维生素K拮抗剂使用者口服抗凝治疗的质量：潜在影响综述
J Clin Med. 2021 Feb 11;10(4):715. doi: 10.3390/jcm10040715.
10
Morbidity and mortality after fragility hip fracture surgery in patients receiving vitamin K antagonists and direct oral anticoagulants.维生素 K 拮抗剂和直接口服抗凝剂治疗患者的脆性髋部骨折手术后的发病率和死亡率。
Thromb Res. 2018 Jun;166:106-112. doi: 10.1016/j.thromres.2018.04.022. Epub 2018 Apr 26.

本文引用的文献

1
Incidence and Predictors of Clinical Outcomes in Patients with Valvular and Nonvalvular Atrial Fibrillation Using Vitamin K Antagonists.使用维生素K拮抗剂的瓣膜性和非瓣膜性心房颤动患者临床结局的发生率及预测因素
Arq Bras Cardiol. 2025 Jan;122(2):e20240147. doi: 10.36660/abc.20240147.
2
Telemedicine-Based Management of Oral Anticoagulation Therapy: Systematic Review and Meta-analysis.基于远程医疗的口服抗凝治疗管理：系统评价和荟萃分析。
J Med Internet Res. 2023 Jul 10;25:e45922. doi: 10.2196/45922.
3
Trends in Oral Anticoagulant Use Among 436 864 Patients With Atrial Fibrillation in Community Practice, 2011 to 2020.2011 年至 2020 年社区实践中 436864 例房颤患者口服抗凝剂使用趋势。
J Am Heart Assoc. 2022 Nov 15;11(22):e026723. doi: 10.1161/JAHA.122.026723. Epub 2022 Nov 8.
4
Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation.利伐沙班在风湿性心脏病相关心房颤动中的应用。
N Engl J Med. 2022 Sep 15;387(11):978-988. doi: 10.1056/NEJMoa2209051. Epub 2022 Aug 28.
5
2021 ESC/EACTS Guidelines for the management of valvular heart disease.2021年欧洲心脏病学会/欧洲心胸外科学会瓣膜性心脏病管理指南。
Eur Heart J. 2022 Feb 12;43(7):561-632. doi: 10.1093/eurheartj/ehab395.
6
Use of Guidelines for Reducing Stroke Risk in Patients With Nonvalvular Atrial Fibrillation: A Review From a Latin American Perspective.非瓣膜性心房颤动患者降低卒中风险指南的应用：拉丁美洲视角的综述
Clin Appl Thromb Hemost. 2018 Jan;24(1):22-32. doi: 10.1177/1076029617734309. Epub 2017 Oct 9.
7
Non-vitamin K antagonist oral anticoagulants compared with warfarin at different levels of INR control in atrial fibrillation: A meta-analysis of randomized trials.非维生素 K 拮抗剂口服抗凝剂与华法林在不同 INR 控制水平下用于房颤的比较：随机试验的荟萃分析。
Int J Cardiol. 2017 Oct 1;244:196-201. doi: 10.1016/j.ijcard.2017.06.004. Epub 2017 Jun 3.
8
Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH.非手术患者心房颤动和静脉血栓栓塞性疾病抗凝剂研究中临床相关非大出血的定义：国际血栓与止血学会科学与标准化委员会的沟通
J Thromb Haemost. 2015 Nov;13(11):2119-26. doi: 10.1111/jth.13140.
9
Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial.利伐沙班与华法林在治疗范围内的时间与比较治疗效果之间的关系：ROCKET AF试验结果
J Am Heart Assoc. 2014 Apr 22;3(2):e000521. doi: 10.1161/JAHA.113.000521.
10
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.利伐沙班与华法林用于非瓣膜性心房颤动。
N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10.

Oral Anticoagulation with VKAs: Quality Above All!

作者信息

Ferreira Letícia Braga, Carmo André Assis Lopes do

机构信息

Unidade de Cardiologia e Cirurgia Cardiovascular do Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, MG - Brasil.

Serviço de Cardiologia e Cirurgia Cardiovascular, Rede Mater Dei de Saúde, Belo Horizonte, MG - Brasil.

出版信息

Arq Bras Cardiol. 2025 Feb;122(2):e20240795. doi: 10.36660/abc.20240795.

DOI:10.36660/abc.20240795
PMID:40105586
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12080706/
Abstract
摘要